Who
Crespo Blas Coll
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Structure Therapeutics.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Sep 2024
- Last trade
- 21 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 22 Sep 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code C | —12,024 at $0.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,008 at $0.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,008 at $0.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $145K4,008 at $36.15 | filing |
| 21 Sep 2026filed 22 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $145K4,008 at $36.15 | filing |
| 21 Sep 2026filed 22 Sep 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code C | —12,024 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $124K10,626 at $11.67 | filing |
| 18 Sep 2026filed 22 Sep 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $124K10,626 at $11.67 | filing |
| 19 Mar 2026filed 23 Mar 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —75,897 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,984 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,984 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —75,897 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $248K11,826 at $20.99 | filing |
| 3 Mar 2026filed 5 Mar 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $248K11,826 at $20.99 | filing |
| 18 Sep 2025filed 22 Sep 2025 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $63K8,106 at $7.74 | filing |
| 1 Jul 2025filed 3 Jul 2025 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,992 at $0.00 | filing |
| 1 Jul 2025filed 3 Jul 2025 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,8091,434 at $6.84 | filing |
| 21 May 2025filed 3 Jul 2025 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —429 at $0.00 | filing |
| 15 Mar 2025filed 18 Mar 2025 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —284,241 at $0.00 | filing |
| 15 Mar 2025filed 18 Mar 2025 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —116,988 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.